Relapsing–Remitting Multiple Sclerosis: Patterns of Response to Disease-Modifying Therapies and Associated Factors: A National Survey
Author:
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Link
http://link.springer.com/content/pdf/10.1007/s40120-014-0019-4
Reference29 articles.
1. De Sa J, Paulos A, Mendes H, Becho J, Marques J, Roxo J. The prevalence of multiple sclerosis in the District of Santarem. Portugal. J Neurol. 2006;253:914–8.
2. Sa MJ, Guimaraes J, Abreu P, Mendes A, Souto BE. Etiopathogenesis, classical immunotherapy and innovative nanotherapeutics for inflammatory neurological disorders. Curr Nanosci. 2011;7:2–20.
3. Mendes A, Sa MJ. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Arq Neuropsiquiatr. 2011;69:536–43.
4. Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014;27:246–59.
5. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655–61.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. E-WE thrombin, a protein C activator, reduces disease severity and spinal cord inflammation in relapsing-remitting murine experimental autoimmune encephalomyelitis;2023-04-17
2. Role of lipoic acid in multiple sclerosis;CNS Neuroscience & Therapeutics;2021-12-28
3. A Novel Digital Care Management Platform to Monitor Clinical and Subclinical Disease Activity in Multiple Sclerosis;Brain Sciences;2021-09-03
4. Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis;Frontiers in Neurology;2020-09-02
5. The effects of vitamin D supplementation on expanded disability status scale in people with multiple sclerosis: A critical, systematic review and metaanalysis of randomized controlled trials;Clinical Neurology and Neurosurgery;2019-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3